Investors

Financial Calendar 2016
16 Feb - Half Year Results
17 Aug - Full Year Results
12 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Bernard Ronchi
Senior Manager, Investor Relations
Phone: +613 9389 3470
bernard.ronchi@csl.com.au
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

CSL Share Price

Visit our CSL Share Price page to access the quote table and price chart.

About CSL

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.

With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 16,000 employees working in more than 30 countries.


ASX Releases

24/05/2016
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season. More.

12/05/2016
IDELVION® (rFIX-FP) - European Commission Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). More.

14/03/2016
Seqirus Presentation to Investors/Analysts
Gordon Naylor, Russell Basser and Brent MacGregor deliver a presentation to investors and analysts during site tours at the Seqirus manufacturing facilities in Liverpool and Holly Springs. More.

07/03/2016
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. More.

29/02/2016
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B. More.

16/02/2016
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016. More.

16/02/2016
Half Year Result 2016
CSL Delivers Exceptional Performance

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2. More.

10/12/2015
Research & Development Investor Briefing
CSL Limited (ASX:CSL; USOTC:CSLLY) conducted its annual research & development briefing for investors on Thursday 10 December 2015. More.

15/10/2015
CSL announces record A$1 billion share buyback
CSL today announced a new on-market share buyback of up to A$1 billion. The new buyback will be the largest ever undertaken by the company as part of its regular buyback program. More.

09/10/2015
CSL Names David Lamont as Chief Financial Officer
CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (CFO), effective 2 January 2016. He will be based at CSL’s headquarters in Parkville, Australia. As announced in August, CSL CFO Mr. Gordon Naylor is transitioning to the role of President of Seqirus, the new global business created from the integration of bioCSL and the newly acquired Novartis influenza vaccines business. More.

09/10/2015
New CHF400 Million & USD100 Million US Private Placement
CSL today announced that on 8 October 2015 it has closed a new CHF400 million and USD100 million private placement in the US. The private placement was foreshadowed in CSL’s full year results announcement in August 2015 More.

12/08/2015
Strong Full Year Result
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP). NPAT grew 10% on a constant currency1 basis, after adjusting for the one-off costs2 associated with the acquisition of the Novartis influenza vaccine business. More.

03/08/2015
CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. More.

31/07/2015
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

28/07/2015
Competitive Advanced Manufacturing - Quite within Reach for Australia
Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia’s largest biotechnology company. The key is to make a serious, strategic effort to attract footloose global investment, especially targeting innovations and ideas developed in Australia. More.

28/07/2015
U.S. FDA Accepts for Review CSL Behring’s BLA for its Novel rVIII-SingleChain Therapy for Patients with Haemophilia A
CSL Limited (ASX:CSL; USOTC: CSLLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIIISingleChain) for the treatment of haemophilia A. In the pivotal clinical trial, rVIIISingleChain met all primary endpoints. More.

17/06/2015
CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
ISTH Congress

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B. More.

23/04/2015
Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012. More.

30/03/2015
European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). More.

11/02/2015
Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%. More.

Prior ASX Releases

>> View the ASX Archive


© 2016 CSL Limited